Anti-BCMA-Anti-CD19-Anti-CD3 Trispecific Molecule

Product Code
AMS.100761-2
$0.00
Order Support
Shipping Information
Product Updates
  • Keep up to date with product offers, resources and news

  • Sign up

The Anti-BCMA-Anti-CD19-Anti-CD3-His Trispecific Antibody is engineered to bind to three different targets simultaneously: 1) BCMA|a B cell antigen that is highly expressed by mature B cells and malignant myeloma cells|2) CD19|a B-cell marker that is a target for many leukemias and lymphomas|and 3) CD3|a T cell receptor activation signal that leads to cytokine secretion. The multi-functionality of this trispecific antibody allows it to bind to BCMA and CD19 on the tumor cell and CD3 on T cells simultaneously|thus bringing T lymphocytes closer to the cancer cells. The binding event targets the tumor while providing co-stimulatory signals that promote T cell expansion and cytotoxicity against BCMA+ and CD19+ cancer cells.
More Information
SKU AMS.100761-2
Size 100 ug
Species Human
Gene synonyms Cluster of Differentiation 19 antibody, B-Lymphocyte Surface Antigen B4 antibody, CVID3 antibody, B-cell maturation antigen antibody, TNFRSF17 antibody, CART antibody, 100761-1, 100761-2
Storage Stable for at least 12 months at -80C. Avoid freeze/thaw cycles.
Shipping Temp -80C (dry ice)
Supplier Name BPS
For more details visit our Immunotherapy: Bispecific and trispecific antibodies page >For more details visit our CAR-T Cell Research page >